Company: ABBV
Filing Date: 2025-02-14
Form Type: 10-K
Source: 0001551152-25-000020
Chunk: 365

Company: AbbVie Inc.
Filing Date: 2025-02-14
Form: 10-K
Item: Item 8
Chunk 365
---
 future periods.The CODM regularly reviews net revenues, net earnings and significant segment expenses and uses net earnings as its principal measure of segment profit or loss. Net earnings and significant segment expenses reviewed by CODM are reported on the Consolidated Statement of Earnings for the years ended December 31, 2024, 2023 and 2022. The CODM uses net earnings as its principal measure of segment profit or loss to compare past financial performance with current performance and analyze underlying business performance and trends. The CODM does not use segment assets to make decisions regarding resources; therefore, the total asset disclosure has not been included.

97     |  2024 Form 10-K

Substantially all of AbbVie's pharmaceutical product net revenues in the United States are to three wholesalers. Outside the United States, products are sold primarily to health care providers or through distributors, depending on the market served. The following tables detail AbbVie's worldwide net revenues:years ended December 31 (in millions)202420232022ImmunologyHumiraUnited States$7,142 $12,160 $18,619 International1,851 2,244 2,618 Total$8,993 $14,404 $21,237 SkyriziUnited States$10,086 $6,753 $4,484 International1,632 1,010 681 Total$11,718 $7,763 $5,165 RinvoqUnited States$4,259 $2,824 $1,794 International1,712 1,145 728 Total$5,971 $3,969 $2,522 OncologyImbruvicaUnited States$2,448 $2,665 $3,426 Collaboration revenues899 931 1,142 Total$3,347 $3,596 $4,568 VenclextaUnited States$1,234 $1,087 $1,009 International1,349 1,201 1,000 Total$2,583 $2,288 $2,009 Elahere(a)United States$477 $— $— International2 — — Total$479 $— $— EpkinlyCollaboration revenues$118 $28 $— International28 3 —